Daily Archives: November 2, 2018

Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director

SYDNEY, Australia and MINNEAPOLIS, Nov. 02, 2018 (GLOBE NEWSWIRE) — Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, announces the appointment of David B. Kaysen as CEO and Managing Director.

Mr. Kaysen brings more than 35 years of experience leading and managing both domestic and international emerging growth companies. He has achieved consistent and solid results with bio-pharmaceutical, medical device, and clinical software/IT companies. He is experienced in the FDA approval process, leading products in revenue growth, and has experience in Australia.

Prior to joining Medibio, Kaysen served as President, CEO and director of Sun BioPharma, Inc., a biopharmaceutical company developing a drug for pancreatic cancer. During his tenure, he successfully completed a reverse merger to form a U.S. publicly traded company, strengthened organization structure with public company experience in key leadership and board roles, and raised in excess of $9 million to advance the lead candidate drug into clinical trials in the U.S. and Australia.

From 2006 until 2013, Kaysen served as President, CEO and director of Uroplasty, Inc., a Minnesota-based publicly traded global medical device company, which he guided through successful clinical trials and grew annual sales from $6.7M in 2007 to $22M in 2013. He also successfully completed four rounds of financing, raising $26.5M to fund company growth.

In previous roles, Kaysen served as President, CEO, and director of Advanced Duplications Services, LLC; President, Chief Executive Officer and a director of Diametrics Medical, Inc., and President, CEO, and director of Rehabilicare, Inc., a global rehabilitation and neuromodulation company, where he grew sales from $4M to $73M in sales over a ten-year period.

In addition to his role on the Board of Sun BioPharma, Mr. Kaysen currently serves in Board of Director roles for privately held healthcare companies, InterRad Medical and Spinal Singularity, and as an Advisory Board member for Ireland-based Atlantic Therapeutics and Minneapolis-based EXB Solutions. Kaysen has also served as an advisor and senior executive for several domestic and European growth-oriented, privately-held healthcare companies.

The appointment of Kaysen follows an extensive search conducted by Medibio and Finnesse Partners for a CEO with proven ability to advance the Company, assist in regulatory and scientific advancements, and guide the technology into commercialization. Our selection process included candidate screening by the recruiting firm, interviews with the executive management team, individual and group interviews with our Board of Directors, a full psychological assessment, and a thorough employment history and personal background check.

Kaysen, a Twin Cities native, brings important relationships and experience to Medibio, which is located in one of the United States’ leading medical technology communities.

“Dave has proven time and time again his ability to lead healthcare companies through periods of critical growth and development, while meeting key regulatory objectives and exceeding financial goals,” said Chris Indermaur, Chairman, Medibio Board of Directors. “We are thrilled to have Dave on board at Medibio, as his experience in the global medical technology space will be invaluable as we continue our mission of focusing on the aiding, screening, diagnosing, and managing of mental health.”

Summary of Key Terms of CEO/Managing Director Contract:

In accordance with ASX Listing Rule 3.16.4, the material employment agreement terms are as follows:

(a) Term: Commencing November 5, 2018
(b) Salary: US$360,000 annually
(c) Incentive Scheme:
(i) Short term Incentive (STI) 50% of base annual salary payable in cash or shares on performance milestones to be agreed
(ii) Long term Incentive (LTI) 10 million Options exercisable at A$0.45 with a 5-year term. Two million options to vest each year, accelerated in the event of a change in control transaction.
(d) Termination:
(i) By the Company: Three months written notice (or payment in lieu).
(ii) By the Executive: Three months written notice.

About Medibio Limited
Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au

Further Information:  Website: www.medibio.com.au
Medibio Enquiries:
Kristi Hamilton
Senior Marketing Communications Manager
Medibio Limited
T: +1 952 232 0934
Australian Media Enquiries:
Peter Taylor
NWR Communications
T: +61 (0) 412 036 231


International business strategy to serve as key area of focus

Schiller Park, Ill., Nov. 02, 2018 (GLOBE NEWSWIRE) — PSAV, a global leader in event experiences, announced today that Nik Rudge has been named the company’s first managing director, international. Rudge will build upon the international business strategy to best align teams in Europe and the Middle East to continue to improve on ways the company serves customers globally.

“Nik has vast international business experience in the events industry having led teams in fast-moving, complex and multicultural environments,” said Ben Erwin, president of PSAV.  “His general approach and business insight aligns very well with our purpose, mission and customer-centric culture at PSAV.  We are eager to leverage Nik’s experience working with shared customers on important events in key meeting and event destinations.”

Rudge most recently served as CEO of GovNet Communications, a public sector business that operates training, forum, conference and expo events. He has also led multi-country divisions for ITE Group and UBM, two market-leading tradeshow and exhibition companies.

“I am excited to join PSAV in a capacity where I can make an immediate impact by applying my knowledge and industry experience,” commented Rudge.  “PSAV has been a longtime industry leader and it’s clear they are on the right path to grow its global footprint.  I am happy to build on today’s success by further developing its business to join the customers’ journey regardless of where in the world they work with PSAV.” 


About PSAV®

PSAV is a global leader in event experiences, providing creative, production, advanced technology and staging services to help meeting professionals deliver more dynamic and impactful experiences at their meetings, trade shows and events. The team consists of more than 9,000 professionals across 1,500 on-site venue locations and 49 branch offices within the United States, Canada, Mexico, Europe, the Caribbean, and the Middle East. It is the trusted partner and exclusive on-site provider of choice at leading venues worldwide. PSAV was recently named to the Forbes 2018 America’s Best Employer list. The company is headquartered in Schiller Park, Ill.  www.psav.com.

Bob Niersbach

Constellation Brands’ $5 Billion CAD ($4 Billion USD) Investment in Canopy Growth Closes Following Shareholder and Canadian Government Approval

VICTOR, N.Y. and SMITHS FALLS, Ontario, Nov. 01, 2018 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (Constellation) (NYSE: STZ and STZ.B) and Canopy Growth Corporation (Canopy Growth or the Company) (TSX: WEED, NYSE: CGC) today announced the closing of Constellation’s $5 billion CAD ($4 billion USD) investment in Canopy Growth, which was previously announced on August 15, 2018. The transaction was approved by an overwhelming majority of Canopy Growth shareholders and has been granted all required regulatory approvals, including by the Canadian government under the Investment Canada Act.

This investment provides Canopy Growth with significant funding needed to build scale in the more than 30 countries currently pursuing federally permissible medical cannabis programs, while establishing the foundation needed to supply new recreational adult-use markets as cannabis becomes legal in markets around the world.

“We’re excited to expand our strategic partnership with Canopy Growth and to begin helping them build the global scale needed to win long-term,” said Rob Sands, chief executive officer, Constellation Brands. “The global cannabis market presents a significant growth opportunity and Canopy Growth is well-positioned to establish a strong leadership position in this fast-evolving category.”

With this investment, Constellation Brands increases its ownership interest in Canopy Growth to approximately 37 percent of outstanding common shares of Canopy Growth and has appointed two members of its executive team, as well as two independent directors, to the Board of Directors of Canopy Growth. Constellation estimates the interest expense associated with this transaction to approximate $55 million before tax with an approximate $0.25 impact on fiscal 2019 comparable basis EPS results. Constellation also continues to evaluate the potential equity in earnings impact from the Canopy Growth investment and related items.

“Our cash position opens up a world of opportunity for us,” said Bruce Linton, chairman and co-chief executive officer, Canopy Growth.  “Relative to our valuation, we have never been in a better position to create shareholder value. This investment was a landmark moment for the entire sector when it was announced. Now that the capital is Canopy’s to deploy, we’re going to quickly get to work increasing our lead by adding strategic assets around the world.”

As previously announced, the transaction includes a restructuring of Canopy Growth’s Board of Directors. Canopy Growth management wishes to thank Chris Schnarr and Murray Goldman for their contributions to the company. Mr. Schnarr and Mr. Goldman sat on the Board as it oversaw a transformative period for Canopy Growth from a small start-up to a global, diversified industry leader. Mr. Schnarr will continue with Canopy Growth and transition into a senior leadership role overseeing medical and therapeutic research commercialization. Subsequently, Canopy Growth management welcomes Constellation’s President and Chief Operating Officer Bill Newlands and Executive Vice President and Chief Financial Officer David Klein, as well as current Constellation Board Members Judy Schmeling, former HSNi LLC chief operating officer, and Robert Hanson, chief executive officer of John Hardy Global Limited, to the Canopy Growth Board. Their leadership and experience will be invaluable as Canopy Growth continues to grow around the world.

About Constellation Brands
Constellation Brands (NYSE: STZ and STZ.B), a Fortune 500® company, is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported brands such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. The company’s beer portfolio also includes Ballast Point, one of the most awarded craft brewers in the U.S., and Funky Buddha Brewery. In addition, Constellation is the world leader in premium wine, selling great brands that people love, including Robert Mondavi, Clos du Bois, Kim Crawford, Meiomi, Mark West, Black Box, Ruffino and The Prisoner. The company’s premium spirits brands include SVEDKA Vodka, Casa Noble Tequila and High West Whiskey.

Based in Victor, N.Y., the company believes that industry leadership involves a commitment to brand building, our trade partners, the environment, our investors and to consumers around the world who choose our products when celebrating big moments or enjoying quiet ones. Founded in 1945, Constellation has grown to become a significant player in the beverage alcohol industry with more than 100 brands in its portfolio; about 40 wineries, breweries and distilleries; and approximately 10,000 talented employees. We express our company vision: to elevate life with every glass raised. To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

About Canopy Growth Corporation
Canopy Growth (TSX: WEED) (NYSE: CGC) is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in 12 countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. For more information visit www.canopygrowth.com.

Forward-Looking Statements
This news release contains forward‐looking statements. All statements other than statements of historical fact are forward‐looking statements. The words “expect,” “intend” and similar expressions are intended to identify forward‐looking statements, although not all forward‐looking statements contain such identifying words. These statements may relate to business strategy, future operations and growth, prospects, plans and objectives of management, as well as information concerning expected actions of third parties. All forward‐looking statements involve risks and uncertainties that could cause actual results to differ materially from those set forth in, or implied by, such forward‐looking statements. The forward‐looking statements are based on management’s current expectations and should not be construed in any manner as a guarantee that such results will in fact occur. Examples of such statements include but are not limited to those related to the anticipated use of proceeds, future expansion and growth, future success, the realization of Canopy Growth’s long‐term strategic vision, the creation of shareholder value, and estimated interest expense and its impact on EPS results. All forward‐looking statements speak only as of the date of this news release and neither Constellation Brands nor Canopy Growth undertakes any obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise. In addition to risks and uncertainties associated with ordinary business operations, the forward‐looking statements contained in this news release are subject to risks and other factors and uncertainties, including that the expected impact and benefits of the transaction may not materialize in the manner expected, or at all; circumstances may warrant that Canopy Growth use the proceeds from the transaction for different purposes than stated above; and other factors and uncertainties disclosed from time‐to‐time in Constellation’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10‐K for the fiscal year ended February 28, 2018 and its Quarterly Report on Form 10‐Q for the fiscal quarter ended August 31, 2018, or in Canopy Growth’s filings with the Canadian Securities Administration or with the United States Securities and Exchange Commission, including its annual information form dated June 28, 2018, which could cause actual future performance to differ from current expectations.

Michael McGrew, Constellation Brands, Media (773) 251-4934
Patty Yahn-Urlaub, Constellation Brands, Investor Relations (585) 678-7483
Jordan Sinclair, Canopy Growth, Media (613) 769-4196
Tyler Burns, Canopy Growth, Investor Relations (855) 558-9333 ext. 122

IHMA ได้ประกาศการร่วมลงทุนครั้งใหม่ในประเทศอินเดียเพื่อการช่วยเหลือของการพัฒนายาต้านการติดเชื้อสำหรับอุตสาหกรรมด้านชีวเภสัชภัณฑ์ทั่วโลก

SCHAUMBURG, Ill., Nov. 02, 2018 (GLOBE NEWSWIRE) — International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA) ซึ่งเป็นบริษัทที่ให้บริการด้านการทดลองและการให้คำปรึกษาให้แก่อุตสาหกรรมด้านชีวเภสัช ซึ่งรวมถึงการพัฒนาของผลิตภัณฑ์ต่างๆ สำหรับการป้องกัน การควบคุมและการรักษาโรคที่ติดเชื้อได้ ประกาศการก่อตั้งของบริษัทในเครือในประเทศอินเดีย (IHMA India, LLP)  บริษัทในเครือจะทำให้ความสามารถของ IHMA ง่ายขึ้นเพื่อให้บริการอุตสาหกรรมการต่อต้านการติดเชื้อทั่วโลก

สิ่งนี้เป็นสิ่งที่ต้องการมากที่สุดสำหรับการต่อต้านการติดเชื้อแบบใหม่ ประเทศอินเดียเป็นตลาดที่มีความสำคัญมากและสิ่งมุ่งเน้นที่สำคัญสำหรับบริษัทที่เกี่ยวกับเภสัชกรรมต่างๆ ที่มีการต่อต้านการติดเชื้่อในการพัฒนาขั้นสุดท้าย แม้ว่า IHMA ได้ทำงานร่วมกับบริษัทที่เกี่ยวกับเภสัชกรรมและการทดลองด้านวิชาการในประเทศอินเดียเป็นเวลาหลายปี IHMA India LLP จะให้ IHMA ก่อตั้งด้วยตัวเองในประเทศอินเดียในการประสานงานและการจัดการด้านการศึกษาเพื่อก่อให้เกิดประโยชน์แก่ชุมชนทางการแพทย์ได้ดียิ่งขึ้น

“ผมมีความยินดีเป็นอย่างยิ่งในการเป็นส่วนหนึ่งของการก่อตั้งบริษัท IHMA แห่งใหม่ และผมรอคอยเพื่อที่จะก่อตั้งชุดบริการที่เกี่ยวกับโมเลกุลและจุลชีววิทยาคลินิกของ IHMA ในประเทศอินเดีย” Dr. Tarun Mathur, CEO ของ IHMA India LLP กล่าว

“IHMA มีความตื่นเต้นเป็นอย่างยิ่งเกี่ยวกับการขยายไปยังประเทศอินเดียของเรา บริษัทแห่งใหม่นี้จะให้ความสามารถและความกว้างขวางเพื่อช่วยเหลือด้านการควบคุมดูแลของอุตสาหกรรมด้านชีวเภสัชและความต้องการด้านการทดลองใช้ด้านคลินิคในภูมิภาค” Dr. Ian Morrissey หัวหน้าฝ่ายวิทยาศาสตร์และเจ้าหน้าที่การพัฒนาที่ IHMA Europe Sàrl

“เราทำงานหนักมากในช่วย 26 ปีที่ผ่านมาเพื่อเพิ่มการช่วยเหลือด้านหลอดเทียมสำหรับลูกค้าที่กำลังพัฒนาด้านจุลชีพของเราในตลาดทั่วโลก  สิ่งอำนวยความสะดวกของเราในประเทศอินเดียจะเพิ่มความทุ่มเทและช่วยเหลือลูกค้า ซึ่งคาดว่าจะศึกษาในตลาดที่สำคัญนี้อย่างมาก” Jack L. Johnson ประธาน/CEO ของ IHMA

เกี่ยวกับ IHMA

IHMA มีการทดลองด้านจุลชีววิทยาอยู่ที่ Schaumburg, IL ประเทศสหรัฐอเมริกา และ Monthey ประเทศสวิสเซอร์แลนด์ และสำนักงานธุรกิจตั้งอยู่ใน Gurugram ประเทศอินเดีย  IHMA เป็นผู้ให้บริการที่สำคัญของการบริการด้านการพัฒนาของยาต้านจุลชีพมากกว่า 25 ปี อาคารปฏิบัติการของเราทั้งในสหรัฐอเมริกาและยุโรปเป็นพันธมิตรกับลูกค้าในวงการเทคโนโลยีชีวภาพ เภสัชกรรม และการตรวจวินิจฉัยทั่วโลก IHMA คือห้องปฏิบัติการอิสระชั้นนำที่เชี่ยวชาญด้านการศึกษาเชิงเฝ้าระวังและการทดลองเชิงคลินิก เป็นหมุดหมายสำคัญบนเส้นต่อเนื่องที่เชื่อมจากการพัฒนายาไปสู่การพาณิชย์ IHAM ใช้ประโยชน์จากเทคโนโลยีที่ล้ำสมัยเพื่อให้เกิดการทดสอบและข้อมูลชั้นดี พร้อมกับความสามารถในกรอบเศรษฐกิจ การบริการของ IHMA สามารถปรับให้สอดคล้องกับความต้องการการทดสอบที่เฉพาะตัวของลูกค้าได้ นี่คือสิ่งยืนยันเส้นทางความสำเร็จด้านการพัฒนายา การพาณิชย์ และการตรวจสอบหลังออกสู่ท้องตลาด
หากต้องการข้อมูลเพิ่มเติม โปรดเยี่ยมชมเว็บไซต์ของ IHMA ที่ www.ihma.com


Igael Hamburg 847-303-5003